Introduction
TSC is an autosomal dominantly inherited disease that causes systemic hamartoma. 1 The main symptoms are SEN and SEGA in the brain, AML in the kidney, and LAM in the lung. 2 As the causative genes of TSC, the TSC1 gene was identified on chromosome 9 and the TSC2 gene on chromosome 16. 3,4 TSC often involves neurological manifestations, such as intellectual disability, epilepsy and autism spectrum disorder. 5 The manifestations and severity of these symptoms vary widely among patients. For example, an older brother might live a very normal social life, whereas the younger brother is bedridden for life as a result of severe intellectual disability.
The symptoms of AML are abdominal pain, a palpable mass, macroscopic hematuria and hypertension, but most patients are asymptomatic until their tumors grow quite large. 6 Therefore, AML might be detected after becoming large. 7 TSC-AML rapidly enlarges in patients aged from their the late teens to early 20s. 6 In association with the disease, bleeding from the tumor can occur and cause a state of shock. The patient complains of severe pain, with anemia advancing rapidly and blood pressure decreasing. In these emergency medical conditions, it is necessary to carry out immediate contrast enhancement CT to confirm the diagnosis and carry out emergent transcatheter arterial embolization or emergency surgery. 8 In Japan, everolimus is available for the treatment of AML ≥4 cm in diameter, and TAE and PN are also carried out. 9 In Western countries, the ITSCCC held in 2012 recommended mTOR inhibitors as the first-line treatment for AML enlarged to ≥3 cm, even when asymptomatic. 10 TAE and PN are recommended as second-line treatments. 10 The major aims of treatment for TSC-AML are to maintain renal function, and to prevent AML rupture and enlargement. 9 It is unclear how long we should continue everolimus treatment for TSC-AML from the first administration. Everolimus can shrink AML, but cannot cure it. Furthermore, long-term administration of everolimus increases the risk of developing gonadal dysfunction and ILD. 11, 12 Therefore, everolimus for TSC-AML should be used appropriately to achieve specific treatment goals. In the present study, we carried out intermittent everolimus treatment for TSC-AML, and examined its effectiveness and usefulness.
Methods
Patients and study design TSC was diagnosed based on the ITSCCC diagnostic criteria in consultation with an internist and a dermatologist. A total of 26 patients met the diagnostic criteria and underwent intermittent everolimus treatment for AML sized ≥4 cm. For each patient, we analyzed the AML reduction rate, the presence or absence of enlargement after everolimus withdrawal, the AML reduction rate on everolimus readministration and the adverse events caused by everolimus. For the reduction ratio of AML, the volume of AML was measured using abdominal CT or MRI images and compared with the volume before starting treatment. Adverse events were investigated using CTCAE v4.0-JCOG (National Cancer Institute, Bethesda, MD, USA). This study was approved by the institutional review board of JR Tokyo General Hospital (no. H26-28).
Exclusion criteria
The following patients were excluded: those with an aneurysm sized ≥5 mm within AML, uncontrollable epileptic seizures despite being treated with anti-epileptic agents, poor respiratory condition as a result of LAM or swallowing disorders and those who were pregnant, or who could not periodically visit the hospital.
Intermittent everolimus treatment
The dose of everolimus was set at 10 mg once a day. An abdominal CT or MRI scan was carried out every 3 months during the treatment period. The "stopping rules" for intermittent everolimus treatment for TSC-AML were a reduction in size of the AML to ≤4 cm by the treatment, everolimus administration for ≥12 months and the reduction of AML reaching a plateau. Even during the everolimus withdrawal period, abdominal CT or MRI was carried out every 3 months to follow up the volume of the AML. If the volume of the AML after withdrawal increased to >70% of the pretherapeutic volume, we restarted the everolimus treatment at the same dose used for the initial treatment.
We carried out blood testing, urinalysis and radiography once a month after treatment initiation, and evaluated adverse events. KL-6 was measured as a sensitive marker for interstitial pulmonary disease. When a grade 3 or more severe adverse event was observed, the treatment was suspended. It was restarted after the adverse event was resolved.
Statistical analysis
Serial tumor volume measurements were analyzed using Wilcoxon's signed-rank test. A P-value of <0.05 was considered statistically significant.
Results

Patient characteristics
We analyzed 26 patients with TSC-AML who underwent intermittent everolimus treatment ( Table 1 ). All of them met the diagnostic criteria for TSC. Their median age was 24 years (range 15-60 years). One of them showed performance status 2 due to intellectual disability and muscle weakness, and four (15%) had AML ≥10 cm in diameter. Two and seven were previously treated with PN and TAE, respectively.
Treatment efficacy
The median initial everolimus treatment period was 9 months (range 3-15 months). The AML volume was measured after the initial treatment, and the volume reduction rate was defined as the percentage change in tumor volume. The reduction rate from the baseline in each case is shown in Figure 1 . The average reduction rate of AML was 67%. Most of the AML reduction was of the solid component (angioma and leiomyoma), and there was only a slight reduction of the lipid component. In most cases, the AML volume decreased markedly after 3 months of treatment. Six months thereafter, the AML hardly shrank, and remained approximately the same size (data not shown). Eight patients (31%) did not have enlargement of AML on everolimus withdrawal. The follow-up period after drug withdrawal for these cases ranged from 9 to 15 months, and is currently ongoing. The remaining 18 patients (69%) resumed treatment with everolimus because they experienced enlargement of AML. The median everolimus withdrawal period was 6 months (range 3-9 months). The dosage of everolimus was also 10 mg per day when resuming administration. Everolimus retreatment reduced the volume of AML in all patients (Fig. 2) . AML shrank significantly 3 months after restarting treatment, as in the initial treatment. A typical case is shown in Figure 3 . The average reduction rate of AML was 61%, which was equivalent to the reduction rate for the initial treatment (Fig. 4) . Of the 18 patients, 12 (66%) discontinued everolimus again. No patients suffered AML rupture or bleeding during everolimus treatment or withdrawal.
Adverse events
Adverse events related to everolimus treatment are shown in Table 2 . All patients developed several adverse events during the initial treatment. Stomatitis developed in 23 (88%) patients. Irregular menstruation was noted in seven (50%) of the 14 female patients, and three of them received hormone treatment. The majority of the everolimus treatment-related adverse events developed in the digestive system, including vomiting, diarrhea, abdominal pain and decreased appetite. A wide variety of adverse events occurred, but most cases were very mild. Grade 3 adverse events were observed in just three patients. All patients improved with symptomatic treatment and resumed everolimus. Only one patient developed ILD. All patients recovered from the adverse events during the everolimus withdrawal period. Adverse events during everolimus retreatment were mild compared with the initial treatment. There were few adverse events in the digestive system like those that occurred frequently during the initial treatment. No adverse event was grade 3 or higher.
Everolimus treatment-related abnormal laboratory test values are shown in Table 3 . All abnormal values were grade 1 or 2. Hematological toxicity was observed in six cases during the initial treatment, but in just two cases during the retreatment period. Among the patients without hematological toxicity during the initial treatment, a total of 11 (42%) had serum KL-6 elevation, five (19%) had proteinuria and three (12%) developed hypertension. These adverse events were also seen during everolimus retreatment: six patients (33%) had serum KL-6 elevation, four (22%) developed proteinuria and hypertension was observed in three (17%). The frequencies of those adverse events were equivalent to or higher than those during the initial treatment period. As the elevation of KL-6 comes with a risk of developing ILD, we carefully follow up patients with elevated serum KL-6 levels. Although patients who had proteinuria continued everolimus, no patients suffered renal dysfunction.
Discussion
In recent years, there have been an increasing number of reports on intermittent molecular targeted drug therapies for renal cell carcinoma and TSC. 13, 14 Rensing et al. reported on the effectiveness of intermittent rapamycin administration for epilepsy associated with TSC.
14 Boulay et al. identified prolongation of inactivation of S6 kinase 1 as an effect of intermittent treatment with everolimus. 15 The advantages of intermittent treatment are sustained drug effects, and the reduction of adverse events and medical costs.
The effect of everolimus for TSC-AML has been investigated in the EXIST-2 and extension studies. 16, 17 In Japan, everolimus was approved for treatment of TSC-AML and TSC-SEGA in 2012. We are thus able to provide new treatment options for patients who cannot undergo surgery or TAE because of complications of TSC. However, few studies have been carried out regarding the duration of the administration of everolimus for TSC-AML. Everolimus treatment for TSC-AML rarely achieves complete remission. 16 In other words, everolimus can shrink AML, but cannot cure it. The effect of AML reduction by everolimus lasts for 6 months after the start of treatment, after which the volume of AML remains the same even if treatment is continued. 9 The risk of rupture of AML sized <4 cm is low. 18 For these reasons, we set the treatment goals for TSC-AML that were presented in the Methods section and carried out intermittent everolimus treatment. The present study is the first report regarding intermittent everolimus treatment for TSC-AML.
Eight of the 26 patients did not experience enlargement of AML for 12 months after the withdrawal of everolimus. We were thus able to avoid unnecessary everolimus treatment for these patients. The AML grew larger in the remaining 18 patients when the drug was stopped. Based on our experience, the median reduction rate in everolimus treatment for TSC-AML was 65%. 9 We felt that treatment should be resumed if the AML increased by more than twofold after everolimus withdrawal. Therefore, we set the cut-off value at 70%. Retreatment reduced AML markedly in all these patients, with a reduction rate equivalent to the initial treatment. The above results thus showed that even the readministration of everolimus for TSC-AML was sufficiently effective. A total of 66% (12/18) of the patients once again reached their treatment goals and accordingly discontinued the administration of the drug again. In the future, these patients might need to repeat the treatment intermittently.
In the present study, the frequency of grade 3 or higher adverse events during the initial treatment with everolimus was 12%, whereas that during retreatment was 0%. The patients recovered from all adverse events during the everolimus withdrawal period. Adverse events during the everolimus retreatment were mild compared with the initial treatment, and there were few such events in the digestive system. This might have been because the patients understood the course of the initial treatment and could properly deal with adverse events during retreatment. The adverse events that occurred during retreatment were minor compared with those that were observed during long-term continued treatment in the EXIST-2 extension studies. Thus, considering these factors, intermittent everolimus treatment was also effective for adverse event management. However, attention should also be paid to the elevation of KL-6, proteinnuria and hypertension at the time of retreatment.
There are three merits of intermittent everolimus treatment for TSC-AML. First, by proposing a treatment goal, we can maintain the patients' motivation for treatment. This is important both at the time of the initial treatment and for retreatment. Second, we can expect recovery from adverse events during the drug holiday. This is also related to the reduction of adverse events during retreatment. Last, but not least, it is possible to avoid unnecessary continuous treatment and reduce the economic burden.
The enlargement of TSC-AML is affected by sex hormones. 19 Therefore, AMLs tend to rapidly enlarge during puberty or pregnancy. 20 Thereafter, the enlargement rate of AML regresses with the decrease of sex hormones. To avoid the enlargement and rupture of AML, it seems important to carry out everolimus treatment during the AML enlargement periods. Intermittent everolimus treatment is reasonable, as it is carried out depending on whether or not the AML is enlarged.
If the AML grows larger after the withdrawal of everolimus treatment, it is necessary to repeat the treatment. Percutaneous cryoablation and radiofrequency ablation are carried out for multiple renal carcinomas associated with von Hippel- Lindau disease and TSC-AML. 21, 22 These treatments involve minimal invasion of the living body and can be repeatedly carried out. Percutaneous ablation therapy will be effective for cases in which intermittent everolimus treatment is carried out repeatedly for TSC-AML. Currently, however, percutaneous ablation treatment for TSC-AML in Japan is not covered by insurance.
The present study had some limitations. First, drug holidays might influence the risk of rupture of aneurysms that are associated with AML. AML with an aneurysm measuring ≥5 mm in size is at high risk of rupture. 18 Therefore, in the present study, patients with an aneurysm ≥5 mm in the AML were excluded. In such cases, treatment with everolimus is started after renal TAE. Second, TSC-associated diseases are usually improved by the initial everolimus treatment. The efficacy of everolimus has also been reported in TSC patients with epilepsy. 23 Therefore, epilepsy might be exacerbated by everolimus withdrawal. In such cases, we continued the administration of everolimus at a reduced dose. In summary, the proper use of intermittent treatment and continuous treatment with reduced doses is necessary depending on the specific characteristics of each individual case.
In conclusion, intermittent everolimus treatment for TSC-AML is effective for AML control and adverse event management. It is important to set goals in the treatment of TSC-AML. The intermittent administration of everolimus for the treatment of TSC-AML can minimize the drug dosage and the occurrence of adverse events, and is considered to be a beneficial treatment option for patients. The standard treatment for angiomyolipoma (AML) associated with tuberous sclerosis complex (TSC) is changing from invasive surgery to mammalian target of rapamycin inhibitors, including sirolimus and everolimus, in order to preserve patients' renal function. 1 Renal complications cause death in 31% of adult patients with TSC.
2 TSC is mostly diagnosed during early childhood; however, it is not known whether long-term mammalian target of rapamycin inhibitor use is safe in young patients. Brakemeier et al. published a review of mammalian target of rapamycin inhibitor treatment for TSC patients and emphasized that TSC patients, especially children, have to be closely monitored during the administration of everolimus for the following reasons: (i) most patients with TSC require long-term treatment; (ii) fat-poor renal tumors with a high degree of vascularization, which are difficult to distinguish from renal malignancies, can be presumed to be AML if they show an early response to everolimus treatment; and (iii) the optimal dosage of everolimus for AML in TSC remains unclear. 3 The article by Hatano et al. showed for the first time the effectiveness of intermittent everolimus treatment for renal AML associated with TSC. 4 After the administration of everolimus, all of the AMLs shrank, and the AMLs in eight out of 26 patients remained smaller after the withdrawal of everolimus. The remaining AML re-grew after the withdrawal of everolimus; however, all of the tumors shrank again after the re-administration of everolimus. Intermittent everolimus treatment might be particularly useful for young patients with AML associated with TSC.
Regarding (i), Hatano et al. proposed three advantages of intermittent therapy: (1) it helps to maintain the patient's motivation for treatment by creating a treatment goal; (2) patients are released from adverse events during drug holidays; and (3) unnecessary continuous treatment is avoided, and the economic burden is reduced. Concerning (ii), some studies, 5 including the current study, have shown that highly vascularized AML exhibit an early response to everolimus treatment (a 67% tumor reduction in 9 months [median value]), supporting Brakemeier's findings. As for the most important query (iii), intermittent everolimus treatment might be useful for identifying the optimal dose of the drug. Bissler et al. detected an association between the rate of renal tumor shrinkage and trough everolimus levels during continuous everolimus treatment for AML-associated TSC. 5 Further study is needed to determine the optimal dose of everolimus, and the optimal duration of the everolimus withdrawal period for AML-associated TSC. 
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